Literature DB >> 30179152

Catenibacillus scindens gen. nov., sp. nov., a C-deglycosylating human intestinal representative of the Lachnospiraceae.

Annett Braune1, Michael Blaut1.   

Abstract

An anaerobic Gram-stain-positive, non-spore-forming and non-motile bacterium isolated from the human gut, designated CG19-1T, capable of cleaving aromatic C-glucosides was characterized using a polyphasic taxonomic approach. Major fermentation products of this asaccharolytic organism were acetate and butyrate when grown on a complex medium. Growth of strain CG19-1T was stimulated by glucose or pyruvate. Growth inhibition was observed in the presence of several phenolic acids including ferulic acid, which nevertheless was reduced to dihydroferulic acid. Strain CG19-1T contained peptidoglycan type A4β l-Orn-d-Asp. The major cellular fatty acids were C16 : 0 and C18 : 1ω9c. The genomic DNA G+C content was 47.1 mol%. Based on its 16S rRNA gene sequence, strain CG19-1T is a member of the Lachnospiraceae. However, sequence identity to other Lachnospiraceae species with validly published names is approximately 93.0 % with Frisingicoccus caecimuris being the most closely related species according to phylogenetic analysis. Based on these findings, it is proposed to create a novel genus, Catenibacillus, and a novel species, Catenibacillus scindens, with the type strain CG19-1T (=DSM 106146T=CCUG 71490T).

Entities:  

Keywords:  Catenibacillus scindens; Lachnospiraceae; aromatic C-glucoside; deglycosylation; flavonoid; human intestinal microbiota

Mesh:

Substances:

Year:  2018        PMID: 30179152     DOI: 10.1099/ijsem.0.003001

Source DB:  PubMed          Journal:  Int J Syst Evol Microbiol        ISSN: 1466-5026            Impact factor:   2.747


  3 in total

Review 1.  Summary of Novel Bacterial Isolates Derived from Human Clinical Specimens and Nomenclature Revisions Published in 2018 and 2019.

Authors:  Erik Munson; Karen C Carroll
Journal:  J Clin Microbiol       Date:  2021-01-21       Impact factor: 5.948

2.  Effects of fulvic acid on growth performance, serum index, gut microbiota, and metabolites of Xianju yellow chicken.

Authors:  Peishi Feng; Qiaoqiao Li; Hanxue Sun; Jinfeng Gao; Xuan Ye; Yi Tao; Yong Tian; Ping Wang
Journal:  Front Nutr       Date:  2022-08-05

Review 3.  Potential Modulatory Microbiome Therapies for Prevention or Treatment of Inflammatory Bowel Diseases.

Authors:  Daan V Bunt; Adriaan J Minnaard; Sahar El Aidy
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.